KRAS and non-small cell lung carcinoma: Although sotorasib was recently approved in the U.S. against KRASG12C-mutant NSCLC [62], KRAS-mutant cancers from multiple sites of origin remain notoriously aggressive and undruggable [63] and direct KRAS inhibition is associated with some toxicity that likely renders such treatments unsuitable for chemoprevention [64].